On October 26, 2018 Senior Director of Corporate Development at Immunomic Therapeutics Inc. Sia Anagnostou will speak at the Precision Lung Cancer World R&D Summit in Boston (Press release, Immunomic Therapeutics, OCT 26, 2018, View Source [SID1234530209]). Anagnostou’s presentation, titled "UNITE Technology as Nucleic Acid & Cell Based Immunotherapy: TERT – LAMP Case Study," will highlight Immunomic’s investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology. Immunomic’s technology platform has the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory, a method that could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer. The investigational UNITE technology is currently being applied as a cancer immunotherapy in a Phase II clinical trial targeting glioblastoma multiforme (GBM). Anagnostou’s presentation will explore the broader potential of UNITE through discussion of the LAMP-based immunotherapy technology, AST-VAC2 (VAC2). VAC2 is an allogeneic cancer immunotherapy being developed by Asterias Biotherapeutics, Inc. in collaboration with Cancer Research UK and is currently in a Phase 1 clinical trial for treatment of non-small cell lung cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Who: Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc.
What: Presentation on Activating Immune Responses in Cancer
When: Monday, October 29 at 4:00 p.m. EDT
Where: Wyndam Boston Beacon Hill, 5 Blossom St., Boston, MA 02114
About UNITE
ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.